Psychotropic Drug Directory Update March 2025
This update contains changes to 30 monographs. The MHRA drug safety updates for sodium valproate were incorporated, including updates to 1.10 Bipolar mood disorder, 3.4 Epilepsy, and 3.9 Peri-natal. Information on Vitamin B1 (thiamine) and Wernick’s encephalopathy in 1.4 Alcohol dependence and abuse and 1.5 Alcohol withdrawal syndrome was updated, and Chapter 7 has also been updated with discontinued and relaunched products.
Revisions: 1.10 Bipolar mood disorder; 1.4 Alcohol dependence and abuse; 1.5 Alcohol withdrawal syndrome; 3.4 Epilepsy; 3.9 Peri-natal.
Minor updates: 1.1 Acute disturbance (AD) including acute agitation, acute psychiatric emergency, and rapid tranquillisation; 1.2 Aggression; 1.7 Attention deficit hyperactivity disorder (ADHD), including hyperkinetic disorder; 1.8 Autistic spectrum disorders (ASD); 1.9 Benzodiazepine dependence and withdrawal; 1.11 Borderline personality disorder (BPD); 1.12 Catatonia; 1.14 Depression, 1.15 Eating disorders; 1.16 Insomnia; 1.19 Panic disorder; 1.20 Post-traumatic stress disorder (PTSD); 1.21 Psychosis and schizophrenia; 1.25 Social anxiety disorder (Social phobia disorder); 1.26 Tourette’s syndrome (Gilles de la Tourette); 1.27 Trichotillomania; 3.6 Hepatic impairment; 3.8 Parkinson’s disease (PD); 4.2.1 Antipsychotics — General; 4.4.4 Valproate (sodium valproate, valproic acid, divalproex sodium, valproate semisodium); 6.4 Central adverse effects; 6.7 Movement disorders; 6.10 Sexual side-effects; 7.0 Psychotropic drugs.